Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate effects of long-term treatment with rilmenidine compared with atenolol on lipid and glucose metabolism and cardiovascular remodeling in hypertension. Material and methods. 37 patients with hypertension were randomized to rilmenidine 1-2 mg/day or atenolol 50-100 mg/day for 26 weeks. Standard oral glucose tolerance test with a parallel measurement of insulin and glucose levels was performed. The “areas under the curve” (AUC) for insulin and glucose were calculated. Plasma lipids, left ventricular mass index (LVMI) and intima-media thickness (IMT) were measured. Brachial artery diameter during reactive hyperemia was used to test endothelium-dependent vasodilatation (EDVD). Results. Blood pressure reduction was equally achieved in both treatment arms. The fasting glucose level increased in the atenolol group from 4.8±0.6 to 5.2±0.7 mmol/l (p<0.01). The AUC of glucose in rilmenidine group decreased from 860±93 to 737±66 mmol/min/l (p<0.05), and it increased from 937±86 to 989±88 mmol/min/l (p<0.05) in the atenolol group. Rilmenidine showed a positive effect on lipid levels, while in the atenolol group a significant decrease of high density lipoprotein was observed. LVMI decreased with rilmenidine by 9.6% (p<0.05) and by 6,9% (not significantly) with atenolol. IMT significantly decreased in the rilmenidine. EDVD slightly increased on rilmenidine, while on atenolol group it remained unchanged. Conclusion. Our data suggest that in hypertensive patients central inhibition of sympathetic drive can produce favorable effects on glucose and lipid metabolism compared with standard β-blockade with a similar antihypertensive efficacy. Rilmenidine also provides beneficial effects on cardiovascular remodeling and altered endothelial function in hypertension.

About the Authors

Y. R. Kasherininov
Almazov Research Institute of Cardiology
Russian Federation

E. K. Shavarova
Almazov Research Institute of Cardiology
Russian Federation

A. A. Shavarov
Almazov Research Institute of Cardiology
Russian Federation

N. V. Vachrameeva
Almazov Research Institute of Cardiology
Russian Federation

A. N. Krutikov
Almazov Research Institute of Cardiology
Russian Federation

E. V. Smirnova
Almazov Research Institute of Cardiology
Russian Federation

A. O. Коnrady
Almazov Research Institute of Cardiology
Russian Federation

E. V. Shlyakhto
Almazov Research Institute of Cardiology
Russian Federation


1. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM.Diabetes Care 1998; 21:597-603.

2. Lindholm LH, Ibsen T Dahlof B.Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patents with diabetes in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:1004-1010.

3. Bousquet P, Dontenwill M, Greney H, Feldman J. Imidazoline Receptors in Cardiovascular and Metabolic Diseases. J Cardiovasc Pharmacol 2000; 35, Suppl. 4: 21-25.

4. Krentz AJ, Evans AJ. Selective imidazoline receptors agonists for metabolic syndrome. Lancet 1998; 351: 152-54.

5. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.BMJ 1989;.298:1152.-1157.

6. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients.Blood Press 1992;1:92-101.

7. Reneland R, Alvarez E, Andersson PE, et al. Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril.J Hum Hypertens 2000;14:175-180.

8. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2002; 288: 2981-97.

9. De Luca N, Izzo R, Fontana D, Iovino G, Argenciano l Vecchione C, Trimarco B. Hemodynamic and metabolic effect of rilmenidine in hypertensive patients with metabolic syndrome X. A Double-Blind Parallel Study versus amlodipine.J Hypertens 2000; 18: 10.

10. Koren MJ, Savage DD, Casale PN, Mensah GA, Ganau A, Devereux RB. Changes in left ventricular mass predict risk in essential hypertension.Circulation 1990; 82:III29

11. Levy D, Salomon M, D’Agonistino R, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.Circulation 1994; 90:1786-1793.

12. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J et al. Reduction of cardiovascular risk by regression of elecrocardiographic markers of left ventricular hypertrophy by the angiotensin enzyme inhibitor, ramipril.Circulation 2001; 104:1615-1621.

13. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabity-Rosei al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.J Hypertens 1995;13:1091-1097

14. Verdecchia P, Schillaci G, Borgioni I, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension.Circulation 1998; 97: 48-45.

15. Bots ML, Dujk JM, Oren A, Grogge D. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence.J Hypertens 2002; 20:2317-2326.

16. Perticone F, Cerevalo R, Rujia A, Ventura G, Iacopino S, Scozzafava A. et al. Prognostic significance of endothelial dysfunction in hypertensive patients.Circulation 2001;104:191-196.

17. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies.JAMA 1996; 275:1507- 1513.

18. Jennings G, Wong J. Regression of Left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis.J Hypertens 1998 Supp l; 16:S29-S34.

19. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metanalysis of 109 treatment studies.Am J Hypertens 1992;5:95-110.

20. Cruickshank JM, Lewes J, Moore EV, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy.J Hum Hypertens 1992; 17:85-90.

21. Schmeider RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy: analysis of 412 published studies.Am J Hypertens 1994;7:25A.

22. Schmeider RE, Schillaci MP, Klingbeil A, Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998; 13:564-569.

23. Zanchetti A, Bond MG, Hennig M. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427.

24. Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The verapamil in hypertension and atherosclerosis study (VHAS): results of the long-term randomized treatment with either verapamil or chlortalidone on carotid intima-media thickness.J Hypertens 1998;16:1667-1676.

25. Pitt B, Byington RP, Rurberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators.Circulation 2000;102:1503-1310.

26. Koldas L, Ayan F, Ikitimur B. Short term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension. Jpn Heart J 2003;44:693-704.

27. Farsang C, Lengyel M, Borbas S, Zorandi A, Dienes BS; VERITAS Investigators. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin 2003;19:205-217.

28. 2003 European Society of Hypertension –European Society of cardiology Guidelines for the Management of Arterial HypertensionJ Hypertens 2003, 21:1001-1053.

29. O’Brien E, Mee F, Atkins N, O’Mally K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol.J Hypertens 1991; 9:573-574.

30. Seltzer S, Allen W, Herron A. Insulin secretion in response to glycemic stimulus. J Clinical Invest 1967;40:323-335.

31. Friedewald WT, Levy RI, Freidricksen DS. Estimation on the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.

32. Devereux RB, Reicheck N. Echocardiographic determination of left ventricular mass in men. Circulation 1977;55:613-618.

33. Dubois D, Dubois F. A formula to estimate the approximate surface area if height and weight are known.Arch Intern Med 1916; 17:863-871.

34. Devereux RB, Alonso DR, Lutas EM Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 7:639-650.

35. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of arterial wall: the direct measurement with ultrasound imaging.Circulation 1986;74:1339-1408.

36. Salonen R, Hapenen A, Salonen JM. Measurement of intima-media thickness of common carotid arteries with high resolution B-mode ultrasonography: inter and intraobsever variability.Ultrasound Med Biology 1991;17:225-230.

37. Mercuri M., Devi K. Quantitative ultrasonographic evaluation of the carotid arteries in hypertension.J Cardiovasc Risk 1995;2:27-33.

38. Celermajer DS. Soresen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.Lancet 1992; 340:1111-1115

39. Lind L, Hall J, Larsson A, Annuk M, Fellstrom B, Lithell H. Evaluation of endothelium-dependent vasodilatation in the human peripheral circulation.Clin Physiol 2000;20 Suppl.6:440- 448.

40. Van Zwieten PA. The Renaissance of centrally acting antihypertensive drugs. J Hypertens 1999; 17 Suppl.3: 15-21.

41. Dallocchio M, Gosse P, Fillastre JP. Rilmenidine, a new antihypertensive agent in the first line treatment of essential hypertension.Presse Med 1991; 20: 1265-71.

42. Luccioni R. Efficacy and acceptability of rilmenidine in 18235 patients over one year. Presse Med, 1995; 124: 1827-64.

43. Scemama M, Fevrier B, Beucler I, Dairou R. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril.J Cardiovasc Pharacol 1995; 26(Suppl 2)S34-S39.

44. Sadowski Z, Szweld H, Kuch-Wocail,. Kubasik A, Januszewicz W, Krupa-Wojciechowska al. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled study. J Hyperten 1998;16 Suppl 3:S29-35.

45. Anichkov DA, Shastak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipids and glucose levels in hypertensive women with metabolic syndrome.Curr Med Res 2005; 21:113-119.

46. Haenni A, Litchel H. Moxonidine improves insulin sensitivity in insulin resistant hypertensives.J Hypertens 1999; 17 Suppl. 3:S29-35.

47. Farsang C, Lengyel M, Borbas S. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).Current Med Research and Opinion 2003;19:206-217)

48. Devereux RB, Dahlof B. Requirements for an informative trial on left ventricular hypertrophy regression.J Hum Hypertension 1994; 8:735-739.

49. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an adrenergic response.J Clin Invest 1983;72:732-738.

50. Sen S, Tarazi RC. Reversal of the myocardial hypertrophy and influence of the adrenergic system.Am J Physiol 1983;244:H97-H101.

51. Palatini P, Majahalme S, Amerena J, Nesbitt S, Vriz O, Michieletto M, Krause L, Julius S. Determinants of left ventricular structure and mass in young subjects with sympathetic overactivity. The Tecumseh Offspring Study.J Hypertension 2000;18:769-776.

52. Millgard J, Lind L. Divergent effects of different antihypertensive drugs on endothelium-dependent vasodilatation in the human forearm.J Сardiovasc Pharmacol 1998; 32:406-412.

53. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?Lancet 2004; 364:1684-1689.

For citation:

Kasherininov Y.R., Shavarova E.K., Shavarov A.A., Vachrameeva N.V., Krutikov A.N., Smirnova E.V., Коnrady A.O., Shlyakhto E.V. THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL. Rational Pharmacotherapy in Cardiology. 2006;2(2):9-17. (In Russ.)

Views: 364

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)